AcceptedAI Generatedhealth An AMR Surveillance Trust Financed by an Antibiotic Levy and Pull-Incentive Clawback, Not Bilateral Aid
Stop asking bilateral donors nicely to keep funding AMR surveillance and instead take away their unilateral ability to zero it out. Concretely: a pooled multilateral AMR Surveillance Trust, financed primarily by a small mandatory levy on antibiotic sales revenue in high- and upper-middle-income countries (modeled loosely on France's air-ticket solidarity levy that funds UNITAID — a mechanism that has generated over a billion dollars for global health without relying on annual appropriations fights), supplemented by a pull-incentive linkage: any pharmaceutical company receiving a market-entry reward or subscription-model payment for a new antibiotic (the kind the UK's own NHS subscription model and the US PASTEUR Act framework are designed to create) contributes a fixed percentage of that reward into the same Trust as a condition of the incentive payment. This ties surveillance financing to the same drug-resistance economy that creates the underlying problem, rather than to a single country's foreign-aid budget line.
The Trust would be governed the way Gavi and the Global Fund are governed — a board with rotating LMIC and donor-country representation, multi-year replenishment cycles voted on by contributing parties collectively rather than unilaterally revocable by one treasury, and transparent formula-based disbursement to national surveillance systems tied to GLASS reporting completeness (so the money follows demonstrated data quality, not political favor). Crucially, disbursements would prioritize exactly the labs Fleming Fund built and just lost funding for, treating this as a bridge-financing emergency in year one rather than starting from zero.
This is not a new idea in structure — it's the same institutional fix global health financing already found for HIV, TB, and malaria decades ago — it has simply never been applied to AMR surveillance specifically, because AMR has always been treated as a side effect of infectious disease programs rather than its own financing category. None of these individual pieces requires new international law — the levy is a domestic tax policy choice replicable country by country, and the pull-incentive clawback is a contract condition attachable to any future antibiotic reward scheme, which means the Trust can start with a coalition of two or three willing governments rather than waiting for universal consensus.
